Evidence map›Paper›PMID 27733412›Full record

ArticleBMJ open2016

Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study.

Li-Bo Yan, Hui-Ying Rao, Yuan-Ji Ma, Lang Bai, En-Qiang Chen, Ling-Yao Du, Rui-Feng Yang, Lai Wei, Hong Tang, CCgenos Study Group

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01293279 (HCV Viral Genotyping Distribution and Genetic Variation in IL28B Distributions Among the Han Ethnic Chinese in China), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01293279 completednot on this map

HCV Viral Genotyping Distribution and Genetic Variation in IL28B Distributions Among the Han Ethnic Chinese in China

TypeobservationalSponsorPeking University People's HospitalRan2011 to 2011Enrolled997ConditionsHepatitis C
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. [Expert consensus on antiviral therapy for HBV/HCV-related hepatocellular carcinoma: a 2021 update].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Article
  4. [Research progress of hepatitis B and C virus co-infection].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
    Review
  5. Review
  6. Article
  7. HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation.Journal of clinical and translational hepatology · 2018
    Review
  8. Review
  9. [Recent advances in the treatment of hepatitis C in 2016].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Li-Bo YanCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, People's Republic of China.
Hui-Ying RaoBeijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, Peking University People's Hospital, Peking University Hepatology Institute, Beijing, People's Republic of China.
Yuan-Ji MaCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, People's Republic of China.
Lang BaiCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, People's Republic of China.
En-Qiang ChenCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, People's Republic of China.
Ling-Yao DuCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, People's Republic of China.
Rui-Feng YangBeijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, Peking University People's Hospital, Peking University Hepatology Institute, Beijing, People's Republic of China.
Lai WeiBeijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, Peking University People's Hospital, Peking University Hepatology Institute, Beijing, People's Republic of China.
Hong TangCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, People's Republic of China.
CCgenos Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesLittle is known about hepatitis B virus (HBV) infection in patients with hepatitis C virus (HCV) infection in China. This study aimed to evaluate the prevalence, clinical characteristics, viral interactions and host genotypes of HBV/HCV dual infection compared with HCV monoinfection. STUDY

designA cross-sectional study.

settingChina. PARTICIPANTS AND

methods997 patients with HCV from 28 university-affiliated hospitals in China were enrolled in this research. Patients were divided into two subgroups.

resultsThe prevalence of HBV infection in patients with HCV was 4.11% (41/997). The age-specific prevalence of HBsAg was 0.70%, 3.97% and 5.85% in groups aged 18-30, 30-50 and >50 years old (p=0.057), respectively. Patients with HBV/HCV dual infection and patients with HCV monoinfection had similar HCV viral loads (5.80±0.89 vs 5.83±1.00 log10 IU/mL, p=0.904). The dominant HCV genotype was 1b in both groups (53.65% vs 56.90%, p=0.493). The protective C allele in IL-28B (rs12979860) was also the dominant allele type in both patient groups (85.36% vs 83.99%, p=0.814). Patients with HBV/HCV dual infection had a higher ratio of liver cirrhosis and hepatic decompensation than patients with HCV monoinfection (39.02% vs 17.69%, p=0.001; 31.70% vs 12.13%, p=0.001).

conclusionsThe HBV burden was moderate in HCV-infected patients in China. Liver cirrhosis was more common in patients with HBV/HCV dual infection, suggesting the need for closer monitoring of dual-infected individuals. TRIAL REGISTRATION NUMBER: NCT01293279; Post-results.

Indexed as

Hepatitis BHepatitis CAdolescentAdultAgedAsian PeopleChinaCoinfectionCross-Sectional StudiesFemaleGenotypeHepacivirusHepatitis B virusHumansInterferon LambdaInterferonsInterferon Lambdainterferon-lambda, humanInterferonsInterleukinsCirrhosisHepatitisHepatitis B virus (HBV)Hepatitis C virus (HCV)

Identifiers

PMID27733412
PMCPMC5073524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.